Tirzepatide at week 2: what early results actually mean

What did @etherealnellie actually say?

She walked viewers through her second week on Zepbound (tirzepatide) and demonstrated how to use the autoinjector pen. She covered three things: rotating injection sites, removing the cap, checking the needle, unlocking the device, pressing and holding for a ten-count, recapping the pen, and disposing of it. That is a reasonable basic tutorial from a real patient perspective.

She mentions doing the injection "above my stomach" this week, implying she rotates between sites. She does not mention dose, storage temperature, or what to do if the injection window does not turn. For a 26,000-view tutorial aimed at people who are new to this medication, those omissions matter.

Does the science back this up?

The core injection mechanics she describes are accurate and consistent with Eli Lilly's published instructions for use. The hold-for-ten-seconds guidance is real. The rotation advice is real. Neither of those points is controversial.

Site rotation is not just a preference. Repeated injections into the same spot cause lipohypertrophy, a localized buildup of fatty tissue that impairs drug absorption. A 2014 study by Gentile et al. in Diabetes Technology and Therapeutics found that insulin absorption was significantly reduced in lipohypertrophic tissue, and the same mechanism applies to subcutaneous GLP-1 injections. Rotating between the abdomen, thigh, and upper arm is a standard clinical recommendation backed by that pharmacokinetic reasoning, not just habit.

Her instruction to check that "the needle is intact" before injecting is also sound. Autoinjector needles are factory-sealed, but visual confirmation before use is a reasonable safety step.

What did they get wrong (or right)?

She gets the fundamentals right. Where the tutorial falls short is in what it skips entirely.

• No mention of the inspection window. Zepbound pens have a gray inspection window. After a successful injection, it turns yellow. If it does not, the dose may not have been delivered. This is in Lilly's official instructions and is probably the single most important thing a first-timer needs to know.
• No mention of storage. Tirzepatide must be refrigerated at 36 to 46 degrees Fahrenheit. It can be kept at room temperature for up to 21 days, but it cannot be frozen or left in a hot car. A patient who did not know this could compromise their medication before injecting.
• No mention of the 15-second hold option. Lilly's current labeling for Zepbound actually recommends holding for 10 seconds, which she states correctly. This one she gets right.
• Disposal guidance is incomplete. She says to "put the lid back on and dispose of it," which is not safe sharps disposal. Used autoinjectors should go into an FDA-cleared sharps container, not a household trash bin. The FDA's guidelines on safe sharps disposal are explicit about this.

To be fair, she is a week-two patient sharing her experience, not a pharmacist. But that context does not reduce the real-world impact of a 26,000-view video that skips sharps safety entirely.

What should you actually know?

If you are starting Zepbound or any subcutaneous GLP-1 medication, the injection technique basics this video covers are a reasonable starting point, but read the full instructions for use that come in the box. They are written in plain language and cover the inspection window, storage, and what to do if you miss a dose.

A few things worth knowing that this video does not mention: never inject into skin that is bruised, scarred, or has existing lipohypertrophy. The abdomen injection zone should be at least two inches from the navel. Upper arm self-injection is technically an approved site but is harder to administer without assistance.

On disposal: the EPA and FDA both recommend a dedicated sharps container. Many pharmacies sell them for under five dollars, and many states have mail-back programs. Recapping a used needle and putting it in the trash creates a real injury and disease transmission risk for waste workers.

Finally, rotating sites is not just about comfort. Consistent rotation is a pharmacokinetic issue. If you always inject in the same spot and develop lipohypertrophy, you may see reduced drug effect over time, not because the medication stopped working, but because the absorption is impaired. That distinction matters when someone is troubleshooting a weight loss plateau.